510(k) K162969
K162969 is an FDA 510(k) premarket notification submitted by DiaSorin, Inc. for the device "LIAISON® CMV IgG and LIAISON® CMV IgG Serum Control Set". The FDA issued a decision of Substantially Equivalent on January 6, 2017. The device falls under product code LFZ (Enzyme Linked Immunoabsorbent Assay, Cytomegalovirus), a Class II device regulated under 21 CFR 866.3175. DiaSorin, Inc. has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- January 6, 2017
- Date Received
- October 24, 2016
- Clearance Type
- Special
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Enzyme Linked Immunoabsorbent Assay, Cytomegalovirus
- Device Class
- Class II
- Regulation Number
- 866.3175
- Review Panel
- MI
- Submission Type